Table 1.
Demographic and clinicopathologic characteristics, and overall survival of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
| Variables | Total cohort | Training cohort | Validation cohort |
|---|---|---|---|
| All patients | 271 | 170 | 101 |
| Year of diagnosis | |||
| 2004-2009 | 108 (39.8%) | 73 (42.9%) | 35 (34.5%) |
| 2010-2015 | 163 (60.1%) | 97 (57.0%) | 66 (65.3%) |
| Gender | |||
| Male | 190 (70.1%) | 114 (67.0%) | 76 (75.2%) |
| Female | 81 (29.8%) | 56 (32.9%) | 25 (24.7%) |
| Ethnicity | |||
| Caucasian | 200 (73.8%) | 119 (70.0%) | 81 (80.1%) |
| African–American | 24 (8.9%) | 14 (8.2%) | 10 (9.9%) |
| Others | 47 (17.3%) | 37 (21.7%) | 10 (9.9%) |
| Age at diagnosis | |||
| ≤60 | 129 (47.6%) | 81 (47.6%) | 48 (47.5%) |
| >60 | 142 (52.3%) | 89 (52.3) | 53 (52.4%) |
| Marital status | |||
| Married | 173 (63.8%) | 108 (63.5%) | 65 (64.3%) |
| Single | 43 (15.9%) | 25 (14.7%) | 18 (17.8%) |
| Divorced/separated | 33 (12.2%) | 22 (12.9%) | 11 (10.8%) |
| Widowed | 22 (8.1%) | 15 (8.8%) | 7 (6.9%) |
| Tumor size | |||
| ≤ 5 cm | 122 (45.0%) | 72 (42.3%) | 50 (49.5%) |
| > 5 cm | 149 (54.9%) | 98 (57.6%) | 51 (50.4%) |
| Grade | |||
| I | 16 (5.9%) | 12 (7.0%) | 4 (3.9%) |
| II | 86 (31.7%) | 50 (29.4%) | 36 (35.6%) |
| III | 155 (57.1%) | 98 (57.6%) | 57 (56.4%) |
| IV | 14 (5.1%) | 10 (5.8%) | 4 (3.9%) |
| TNM stage | |||
| I | 86 (31.7%) | 52 (30.5%) | 5 (4.9%) |
| II | 67 (24.7%) | 36 (21.1%) | 34 (33.6%) |
| III | 62 (22.8%) | 41 (24.1%) | 31 (30.6%) |
| IV | 42 (15.4%) | 32 (18.8%) | 21 (20.7%) |
| Unknown stage | 14 (5.1%) | 9 (5.2%) | 10 (9.9%) |
| T stage | |||
| T1 | 101 (37.2%) | 61 (35.8%) | 40 (39.6%) |
| T2 | 83 (30.6%) | 47 (27.6%) | 36 (35.6%) |
| T3 | 61 (22.5%) | 45 (26.4%) | 16 (15.8%) |
| T4 | 22 (8.1%) | 15 (8.8%) | 7 (6.9%) |
| TX | 4 (1.4%) | 2 (1.1%) | 2 (1.9%) |
| N stage | |||
| N0 | 218 (80.4%) | 133 (78.2%) | 85 (84.1%) |
| N1 | 35 (12.9%) | 23 (13.5%) | 12 (11.8%) |
| NX | 18 (6.6%) | 14 (8.2%) | 4 (3.9%) |
| M stage | |||
| M0 | 215 (79.3%) | 129 (75.8%) | 86 (85.1%) |
| M1 | 42 (15.4%) | 32 (18.8%) | 10 (9.9%) |
| MX | 14 (5.1%) | 9 (5.2%) | 5 (4.9%) |
| Surgery | |||
| No surgery | 111 (40.9%) | 95 (55.8%) | 35 (34.6%) |
| Yes | 160 (59.0%) | 75 (44.1%) | 66 (65.3%) |
| Chemotherapy | |||
| Yes | 102 (37.6%) | 72 (42.3%) | 30 (29.7%) |
| No/unknown | 169 (62.3%) | 98 (57.6%) | 71 (70.2%) |
| Radiation | |||
| Yes | 26 (9.5%) | 17 (10.0%) | 9 (8.9%) |
| No/unknown | 245 (90.4%) | 153 (90.0%) | 92 (91.0%) |